Clinical Update on Anti-CD20 Therapeutics for Patients with Relapsing Multiple Sclerosis

Clinical Update on Anti-CD20 Therapeutics for Patients with Relapsing Multiple Sclerosis is organized by AcademicCME.

Program Dates: Apr 16, 2024 - Apr 15, 2025

Description:
This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, led by Dr. Mark Freedman, will first cover the topic of b-cells and anti-CD20 as therapeutic targets in the multiple sclerosis (MS) treatment landscape. Following, recent clinical trial data of anti-CD20 monoclonal antibody therapeutics to treat patients with relapsing multiple sclerosis will be reviewed, including key differences among both approved and emerging agents. Dr. Freedman will conclude with a summary of best practices for developing individualized treatment plans as well as practical considerations for switching disease modifying therapies to improve outcomes for patients with MS.

Learning Objectives:

• Review the current science and clinical trial data for anti-CD20 monoclonal antibody therapeutics to treat patients with relapsing multiple sclerosis.
• Review effective measurements of disease activity and therapeutic efficacy which align with appropriate biomarkers and various pathologic processes that drive multiple sclerosis.
• Apply updated strategies and recent data to effectively switch therapies hen there is opportunity to improve outcomes.